ArticleJournal of clinical pharmacology2023
In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
Article in Journal of clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno-Oncology Combination Therapy.Clinical pharmacology and therapeutics · 2026Article
- Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment.British journal of cancer · 2026Article
- Pharmacokinetic insights into atezolizumab SC: viability of extended dosing intervals beyond the standard regimen.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
- Article
- A comparison of pharmacometric software programs for atezolizumab population pharmacokinetic simulation.European journal of clinical pharmacology · 2026Article
- Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens.PharmacoEconomics · 2025Article
- Case Report: Unexpected non-pathogenic autoantibodies without clinical involvement following PD-L1 blockade.Frontiers in immunology · 2025Article
- An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab.Targeted oncology · 2024Article
- Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.British journal of cancer · 2024Article
- Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients.CPT: pharmacometrics & systems pharmacology · 2023Observational
- Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies.British journal of cancer · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Atezolizumab, a humanized monoclonal antibody against programmed cell death ligand 1 (PD-L1), was initially approved in 2016, around the same time that the sponsor published the minimum serum concentration to maintain the saturation of receptor occupancy (6 μg/mL). The initially approved dose regimen of 1200 mg every 3 weeks (q3w) was subsequently modified to 840 mg q2w or 1680 mg q4w through pharmacokinetic simulations. Yet, each standard regimen yields steady-state trough concentrations (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.